Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication errors to double-strand breaks (DSBs) induced by ionising radiation or replication fork collapse. The DNA damage response (DDR) is a coordinated signalling network that detects these lesions, arrests the cell cycle to allow repair, and — if damage is irreparable — initiates apoptosis or permanent senescence. The architecture of the DDR is hierarchical: sensor kinases (ATM, ATR) phosphorylate hundreds of substrates, transducer kinases (CHK1, CHK2) amplify and distribute the signal, and effector proteins execute the cellular response.
When a DSB occurs, the MRN complex (MRE11–RAD50–NBS1) detects the broken DNA ends within seconds and recruits ATM kinase. Activated ATM phosphorylates histone H2AX (γH2AX) across megabase domains flanking the break, creating a scaffold for further DDR protein recruitment. Simultaneously, ATM phosphorylates CHK2 (Thr68), p53 (Ser15), and BRCA1 (Ser1387/1423), coordinating G1/S arrest (via p53→p21), intra-S phase arrest (via CDC25A degradation), and G2/M arrest (via CHK2→CDC25C inhibition), while promoting homologous recombination repair through BRCA1.
When a DSB occurs, the MRN complex (MRE11–RAD50–NBS1) detects the broken DNA ends within seconds and recruits ATM kinase. Activated ATM phosphorylates histone H2AX (γH2AX) across megabase domains flanking the break, creating a scaffold for further DDR protein recruitment. Simultaneously, ATM phosphorylates CHK2 (Thr68), p53 (Ser15), and BRCA1 (Ser1387/1423), coordinating G1/S arrest (via p53→p21), intra-S phase arrest (via CDC25A degradation), and G2/M arrest (via CHK2→CDC25C inhibition), while promoting homologous recombination repair through BRCA1.
DNA Damage Response Pathway
The MRN complex (MRE11 nuclease, RAD50 structural ATPase, NBS1 adaptor) recognises DNA double-strand break ends within seconds of formation. NBS1 directly contacts and recruits ATM kinase to the damage site via its C-terminal ATM-binding motif.
MRN-stimulated ATM undergoes autophosphorylation at Ser1981, releasing active monomers that spread along chromatin. ATM phosphorylates histone H2AX at Ser139 (creating γH2AX) across megabase domains, amplifying the damage signal and recruiting MDC1, RNF8, and RNF168.
ATM-phosphorylated BRCA1 is recruited to DSBs via the RNF8/RNF168/RAP80 ubiquitin pathway. BRCA1 promotes DNA end resection (generating 3′ ssDNA overhangs) and bridges to PALB2–BRCA2–RAD51, catalysing template-directed strand invasion for high-fidelity repair.
Germline mutations in ATM (ataxia-telangiectasia), BRCA1/BRCA2 (hereditary breast/ovarian cancer), CHEK2 (moderate breast cancer risk), and TP53 (Li-Fraumeni syndrome) cause distinct hereditary cancer syndromes defined by the specific step in the DDR pathway that fails. Somatic DDR gene mutations in sporadic cancers accumulate after initial tumour-suppressor loss — particularly TP53 mutation (>50% of all cancers), which eliminates the apoptotic safety net and allows cells with irreparable DNA damage to survive and proliferate.
DNA-repair defects can create treatment vulnerabilities, but the biomarker cannot be reduced to a gene name. PARP-inhibitor evidence depends on tumour type, germline or somatic status, homologous-recombination context, line of therapy and regimen. ATM loss is being studied with ATR and other checkpoint inhibitors but is not interchangeable with BRCA1/2 loss. MSI-high or mismatch-repair-deficient status has indication-specific immunotherapy evidence. Platinum sensitivity and resistance also vary by disease and co-alterations.
What is the difference between ATM and ATR in the DNA damage response?
ATM primarily responds to DNA double-strand breaks (DSBs) and is activated by the MRN complex. ATR responds to single-stranded DNA (ssDNA) arising from replication fork stalling, base excision repair intermediates, or nucleotide excision repair. ATM signals through CHK2; ATR signals through CHK1. Both converge on common effectors including p53 and CDC25 phosphatases.
What is synthetic lethality in the context of DNA repair?
Synthetic lethality occurs when simultaneous loss of two genes is lethal while loss of either alone is survivable. BRCA1/2-deficient cancer cells cannot perform homologous recombination; when PARP (needed for SSB repair) is also inhibited, unrepaired SSBs collapse replication forks into DSBs that cannot be repaired, selectively killing tumour cells while sparing HR-proficient normal cells.
What is BRCAness?
BRCAness refers to a genomic phenotype in tumours without BRCA1/2 mutations that nonetheless exhibit HR deficiency, characterised by high genomic loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions. BRCAness from other DDR gene mutations (ATM, PALB2, RAD51C) also predicts PARP inhibitor sensitivity.
Understand how tumor suppressor genes — including TP53, BRCA1, PTEN, and RB1 — act as the genome's brakes, and what happens when they are lost in cancer.
Understand BRCA1 in homologous recombination, how germline and tumour findings differ, what HRD can and cannot establish, and why PARP evidence is context-specific.
How ATM coordinates the DNA-damage response, what germline and tumour alterations mean, and why ATM loss is not interchangeable with BRCA deficiency.
Learn how different types of gene mutations — point mutations, deletions, amplifications, and fusions — drive cancer and inherited disease, with real examples from TP53, KRAS, and BRCA1.
Tumor Suppressor Networks
Tumour suppressor genes encode proteins that actively restrain cell proliferation, promote DNA repair, or eliminate dama…
Homologous Recombination Repair
Homologous recombination (HR) repairs DNA double-strand breaks primarily in S/G2, when a sister chromatid is available a…
Cell Cycle Regulation Genes
Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regula…
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
EGFR–KRAS–BRAF–MEK–ERK Signalling Pathway in Cancer
The EGFR signalling pathway converts extracellular EGF binding into intracellular proliferative and survival signals via…
PI3K/AKT/mTOR Signalling Pathway
The PI3K/AKT/mTOR pathway integrates growth-factor, nutrient and energy signals to regulate cell survival, growth and me…